Literature DB >> 2743135

Does cholecystokinin colocalize with dopamine in the human substantia nigra?

J M Palacios1, M Savasta, G Mengod.   

Abstract

In situ hybridization was used to examine the distribution of neurons containing cholecystokinin (CCK) mRNA in human, monkey and rat brain. In rat and monkey brain CCK mRNA was visualized in the substantia nigra pars compacta and in the ventral tegmental area. The dopaminergic cell bodies in the human substantia nigra did not however show detectable amounts of CCK mRNA. Low levels of CCK mRNA were observed in the nucleus paranigralis, the human equivalent of the rodent ventral tegmental area. High levels of CCK mRNA were seen in other regions of the same brains including the cortex and the hippocampus. Thus, the adult human substantia nigra dopaminergic cells, in contrast to primate and rodent substantia nigra, do not express CCK. These results question the hypothesis of an involvement of CCK in the regulation of dopaminergic neurons and help to explain the absence of decreased CCK levels in the caudate and putamen of Parkinson's disease victims.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2743135     DOI: 10.1016/0006-8993(89)90733-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

Review 1.  Dopaminergic neurones: much more than dopamine?

Authors:  Vincent Seutin
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

2.  The use of in situ hybridization histochemistry for the study of neuropeptide gene expression in the human brain.

Authors:  G Mengod; J L Charli; J M Palacios
Journal:  Cell Mol Neurobiol       Date:  1990-03       Impact factor: 5.046

3.  Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia.

Authors:  M Schalling; K Friberg; K Seroogy; P Riederer; E Bird; S N Schiffmann; P Mailleux; J J Vanderhaeghen; S Kuga; M Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.